PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biopharmaceutical company developing autologous cell-based therapies for chronic kidney disease, which entered the public markets through a SPAC merger in 2022. The company submitted an S-1/A amendment to its SEC registration statement in August 2022, a procedural step in the post-merger share registration process following its de-SPAC transaction. ProKidney operates in the healthcare and biotechnology sector, with its lead program focused on preserving residual kidney function in patients with progressive chronic kidney disease. The filing reflects the company's active capital markets activity during the second half of 2022. To access complete SPAC filing histories, sponsor profiles, and deal analytics for ProKidney and hundreds of other healthcare SPAC transactions, sign up for a free account at SpacDesk.